Moderna's mRNA Melanoma Data And Fast Track Status Shape Oncology Story [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab in advanced melanoma at the 2026 AACR Annual Meeting. The company reports encouraging response rates and a favorable safety profile for the investigational combination in early stage testing. The U.S. FDA has granted Fast Track designation to the mRNA-4359 and pembrolizumab combination in this setting. For investors tracking NasdaqGS:MRNA, this update fits into Moderna's efforts to extend its mRNA technology beyond infectious disease vaccines into oncology. Cancer immunotherapy is an active area of drug development, and melanoma in particular has been a focus for treatments that work alongside checkpoint inhibitors like pembrolizumab. Early clinical data in this area can help you understand where Moderna is trying to build its next wave of potential products. Looking ahead, the upcoming AACR presentation and Fast Track status outline a clearer path for
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- BMY Stock: Analysts See 16% Upside and a Strong Buy [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb (BMY) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BMY&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "buy" MarketBeat
- Bristol-Myers Squibb Collaboration Adds New Dimension To Oncology Valuation Story [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb: The Market Is Not Pricing The Growth Portfolio That Replaces The Patent Cliff [Seeking Alpha]Seeking Alpha
- The innovators working to make in vivo cell therapy a reality [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 4/17/26 - Form DEFA14A
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- BMY's page on the SEC website